View Older Stories View More Recent Stories

Aug 10, 2022 06:47AM Bristol-Myers Squibb (BMY) and 2seventy (TSVT) Report Positive Topline Results from KarMMa-3 Trial
Aug 10, 2022 06:45AM Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in
Aug 3, 2022 04:16PM Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
Jul 29, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports CheckMate -914 Trial Evaluating Opdivo Plus Yervoy Did Not Meet Endpoint
Jul 29, 2022 06:59AM Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
Jul 27, 2022 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
Jul 22, 2022 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab)
Jul 22, 2022 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Met
Jul 21, 2022 06:59AM Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare Industry
Jul 20, 2022 06:59AM Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
Jul 19, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces Extension of Turning Point (TPTX) Tender Offer
Jul 19, 2022 06:59AM Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
Jun 27, 2022 06:04AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Jun 24, 2022 07:05PM U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Jun 24, 2022 12:52PM Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
Jun 24, 2022 12:51PM New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
Jun 20, 2022 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Jun 15, 2022 04:16PM Bristol-Myers Squibb (BMY) Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Jun 15, 2022 04:16PM Bristol Myers Squibb Announces Dividend
Jun 15, 2022 04:16PM Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Jun 8, 2022 06:59AM Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
Jun 7, 2022 06:59AM Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 6, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes
Jun 6, 2022 06:59AM Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Meta
Jun 6, 2022 06:59AM Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Met
Jun 3, 2022 05:01PM Bristol-Myers Squibb (BMY) Withdraws Supplemental BLA for Reblozyl for Non-transfusion Dependent (NTD) Beta Thalassemia
Jun 3, 2022 04:59PM Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
Jun 3, 2022 06:59AM Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
Jun 3, 2022 06:59AM Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Jun 2, 2022 11:02AM Bristol-Myers Squibb (BMY) Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
Jun 2, 2022 11:01AM Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
Jun 2, 2022 06:59AM Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 1, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
Jun 1, 2022 06:59AM Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
May 28, 2022 07:38AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 27, 2022 06:11PM U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 26, 2022 05:01PM Bristol-Myers Squibb (BMY) Reports Phase 2 PILOT Study Data of CAR T cell Therapy Breyanzi Shows Substantial Durable Responses
May 26, 2022 05:00PM Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line
May 26, 2022 06:59AM Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
May 19, 2022 06:59AM Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
May 16, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports CheckMate -901 Trial Did Not Meet Enpoints
May 16, 2022 06:59AM Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carc
May 13, 2022 07:00AM Bristol-Myers Squibb (BMY) Sells Manufacturing Facility in East Syracuse, New York to LOTTE
May 13, 2022 06:59AM LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
May 12, 2022 07:31AM BridgeBio Pharma Inc. (BBIO) Enters Exclusive License Agreement with Bristol Myers Squibb (BMY) to Develop and Commercialize BBP-398
May 12, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports POETYK PSO Trial Data Showing Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
May 12, 2022 06:59AM New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
May 10, 2022 10:47AM Evotec (EVO) and Bristol Myers Squibb (BMY) Extend and Expand Strategic Partnership in Protein Degradation
View More Recent Stories View Older Stories